{"ticker": {"uuid": "c54d7c9b-29e6-4f69-80f6-14054a23e3ee", "symbol": "ASND", "name": "Ascendis Pharma AS", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating", "summary": "J.P. Morgan has reiterated its Buy rating on Ascendis Pharma A/S (ASND.US) stock. The analyst maintained a price target of $170.00, suggesting potential upside for investors.", "url": "https://news.futunn.com/en/post/74780172/jp-morgan-maintains-ascendis-pharma-a-s-asndus-with-buy", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-19T19:09:11", "published_display": "19 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S (ASND) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Ascendis Pharma A/S (ASND) currently has an earnings forecast score of 8.95 and an average price target of $254.00 from 20 analysts, with a \"Strong Buy\" rating. Analysts expect the company's next quarter revenue to be $384.76M and EPS to be $1.70, a significant improvement from t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asnd/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:35", "published_display": "18 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (NASDAQ: ASND) nets $187.5M from FDA PRV sale", "summary": "Ascendis Pharma (NASDAQ: ASND) announced the sale of its U.S. Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash to an undisclosed buyer. This PRV was granted following the FDA approval of YUVIWEL\u00ae (navepegritide) in February 2026. The transaction is ", "url": "https://www.stocktitan.net/sec-filings/ASND/6-k-ascendis-pharma-a-s-current-report-foreign-issuer-ed53c0783f11.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:35", "published_display": "17 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $326", "summary": "Wells Fargo has reiterated its Buy rating for Ascendis Pharma A/S (ASND.US) and maintained its price target of $326. This indicates the firm's continued confidence in the company's stock performance.", "url": "https://www.moomoo.com/news/post/71663488/wells-fargo-maintains-ascendis-pharma-a-s-asndus-with-buy", "source_name": "Moomoo", "published_at": "2026-06-17T16:10:01", "published_display": "17 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Powerhouse with 36.97% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxObXllQTZhNmhsWUFVNDZlSjBsc2t5OWswVjYxTEd1alBOb3BpSUF2eHMzTDlLNUhpM1JfUXZJcmtaTU5ycjBDeTRQTEV0dndMZnBnWFJEalB3RTFpVzZsRGNVb1B3S2cwbEF0OGRjTlF2WmVIQ0ZWZk1weUR0S2R1YTkzb29rZTl5S3hMSmNRQjRvNXJNX1hQejFoQVZ6YnU5TVBBRkduNnJkZEJkRGdEZEZUdE13S0x6clNJWVRvcFI1emVvZFZzVklsdW5xV1ZGYlRGUw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T09:15:40+00:00", "published_display": "15 Jun 2026 09:15", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Long-term TransCon PTH data from Ascendis Pharma (ASND) show sustained benefits", "summary": "Ascendis Pharma reported positive 3.5-year data from its Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism. The study demonstrated sustained efficacy, safety, and improvements in quality of life and key biochemical markers. Patients ma", "url": "https://www.stocktitan.net/sec-filings/ASND/6-k-ascendis-pharma-a-s-current-report-foreign-issuer-9306be65471e.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:09:29", "published_display": "15 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - Slideshow", "summary": "Ascendis Pharma A/S (ASND) presented a slideshow at the Endocrine Society's Annual Meeting (ENDO 2026). The company published a slide deck in conjunction with this event. This article was prepared by Seeking Alpha's transcripts team.", "url": "https://seekingalpha.com/article/4914923-ascendis-pharma-a-s-asnd-presents-at-endocrine-societys-annual-meeting-endo-2026-slideshow", "source_name": "Seeking Alpha", "published_at": "2026-06-15T06:09:29", "published_display": "15 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ASND) Risk Channels and Responsive Allocation", "summary": "This article analyzes Ascendis Pharma A/s (NASDAQ: ASND) using AI models, identifying a positive near-term sentiment while noting potential mid-term weakness within a long-term strong context. It outlines specific institutional trading strategies including position trading, momen", "url": "https://news.stocktradersdaily.com/news_release/98/ASND_Risk_Channels_and_Responsive_Allocation_061326081402_1781396042.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-13T20:38:43", "published_display": "13 Jun 2026 20:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma Reports Sustained Efficacy and Safety of TransCon PTH in Phase 3 PaTHway Trial for Hypoparathyroidism After Three and a Half Years", "summary": "Ascendis Pharma announced positive long-term results from its Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The treatment demonstrated sustained efficacy and safety over three and a half years, showing significant improvements in ", "url": "https://www.quiverquant.com/news/Ascendis+Pharma+Reports+Sustained+Efficacy+and+Safety+of+TransCon+PTH+in+Phase+3+PaTHway+Trial+for+Hypoparathyroidism+After+Three+and+a+Half+Years", "source_name": "Quiver Quantitative", "published_at": "2026-06-13T20:10:00", "published_display": "13 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hormone shot helps hypoparathyroidism patients cut daily calcium and vitamin D", "summary": "Ascendis Pharma announced positive long-term Phase 3 data for their drug TransCon PTH, showing sustained efficacy and safety for adults with hypoparathyroidism. The treatment helped 86% of patients meet a multi-component endpoint and allowed 100% to achieve independence from acti", "url": "https://www.stocktitan.net/news/ASND/phase-3-data-show-trans-con-pth-replicated-systemic-actions-of-umpzb1yzp30n.html", "source_name": "Stock Titan", "published_at": "2026-06-13T19:38:43", "published_display": "13 Jun 2026 19:38", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase 3 Data Show TransCon\u00ae PTH Replicated Systemic Actions", "summary": "Ascendis Pharma A/S announced Week 182 data from its Phase 3 PaTHway Trial, demonstrating that TransCon PTH (palopegteriparatide) provided sustained efficacy and safety in adults with hypoparathyroidism over three and a half years. The treatment replicated the systemic actions of", "url": "https://www.globenewswire.com/news-release/2026/06/13/3311416/0/en/phase-3-data-show-transcon-pth-replicated-systemic-actions-of-endogenous-pth-through-week-182-in-adults-with-hypoparathyroidism.html", "source_name": "GlobeNewswire", "published_at": "2026-06-13T16:00:00", "published_display": "13 Jun 2026 16:00", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Ascendis Pharma Stock Gaining Friday? - Ascendis Pharma (NASDAQ:ASND)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPSV9USFhQMV9rV0YtYU1NSlhQc3BkSFphaEVTR0E4bmlhbEdEdldrdlRWeXlIZzNEZThxS3IwOHhBUUJzUDVwMzI4c2hDclpGVFVOUkNPR3plVzJ6VmVoT1FVaGFJWXdqa1dBYTRCUHBfbUtsTTlWRmVWWWF4MkNxN2NGTktQemhfbERtM2ZpUDBJQ2ZvNGxWa01xT2xkYWxabmc?oc=5", "source_name": "Benzinga", "published_at": "2026-06-12T16:29:22+00:00", "published_display": "12 Jun 2026 16:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Ascendis Pharma Stock Gaining Friday?", "summary": "Ascendis Pharma A/S (NASDAQ: ASND) stock rose Friday after the company reported positive five-year results from its Phase 2 PaTH Forward trial for TransCon PTH (palopegteriparatide), a treatment for hypoparathyroidism. The trial demonstrated sustained efficacy and safety, with mo", "url": "https://www.sahmcapital.com/news/content/why-is-ascendis-pharma-stock-gaining-friday-2026-06-12", "source_name": "Sahm", "published_at": "2026-06-12T13:39:40", "published_display": "12 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years", "summary": "Ascendis Pharma announced that its investigational drug, TransCon PTH, demonstrated sustained efficacy and safety for up to 5 years in patients with hypoparathyroidism. Data from the Phase 2 PaTH Forward study showed that a majority of patients maintained independence from conven", "url": "https://www.moomoo.com/news/post/71413605/ascendis-pharma-says-transcon-pth-shows-sustained-efficacy-at-5?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-12T13:09:38", "published_display": "12 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 86, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five-year TransCon PTH trial results reported by Ascendis Pharma (ASND)", "summary": "Ascendis Pharma A/S reported positive 5-year (Week 266) results from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The trial demonstrated sustained efficacy and safety, replicating the systemic actions of natural parathyro", "url": "https://www.stocktitan.net/sec-filings/ASND/6-k-ascendis-pharma-a-s-current-report-foreign-issuer-dfda8d37897c.html", "source_name": "Stock Titan", "published_at": "2026-06-12T09:40:13", "published_display": "12 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis boasts of long-term Yorvipath data for hypoparathyroidism", "summary": "Ascendis Pharma announced new long-term data from a Phase 2 trial of its hypoparathyroidism treatment, Yorvipath (palopegteriparatide). The data indicate sustained efficacy over five years, with the hormone replacement therapy showing a beneficial impact on target organs.", "url": "https://seekingalpha.com/news/4602771-ascendis-boasts-long-term-yorvipath-data-hypoparathyroidism", "source_name": "Seeking Alpha", "published_at": "2026-06-11T20:39:23", "published_display": "11 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5-Year Phase 2 Data Show TransCon\u00ae PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism", "summary": "Ascendis Pharma announced 5-year Phase 2 data from its PaTH Forward Trial, demonstrating sustained efficacy and safety of TransCon PTH in adults with hypoparathyroidism. The treatment replicated endogenous PTH actions, showing benefits in kidney function, bone mineral density, an", "url": "https://www.globenewswire.com/news-release/2026/06/11/3310783/0/en/5-Year-Phase-2-Data-Show-TransCon-PTH-Replicated-Systemic-Actions-of-Endogenous-PTH-in-Adults-with-Hypoparathyroidism.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T19:39:23", "published_display": "11 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5-year trial: drug frees most hypoparathyroidism patients from supplements", "summary": "Ascendis Pharma reported positive 5-year Phase 2 data for TransCon PTH in adults with hypoparathyroidism, showing sustained efficacy and safety. The drug normalized calcium levels, improved kidney function, and enhanced quality of life, with 82% of patients meeting the multi-comp", "url": "https://www.stocktitan.net/news/ASND/5-year-phase-2-data-show-trans-con-pth-replicated-systemic-actions-cbbltuk82qs8.html", "source_name": "Stock Titan", "published_at": "2026-06-11T19:39:23", "published_display": "11 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma grants 27,030 employee warrants at $213.23 per share", "summary": "Ascendis Pharma's board of directors has issued 27,030 warrants to employees, allowing them to subscribe for shares at $213.23 each. The warrants will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the subsequent three years, cont", "url": "https://www.investing.com/news/sec-filings/ascendis-pharma-grants-27030-employee-warrants-at-21323-per-share-93CH-4736124", "source_name": "Investing.com", "published_at": "2026-06-11T00:09:46", "published_display": "11 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Ascendis Pharma A/S Current Report (Foreign Issuer) | ASND SEC Filing - Form 6-K", "summary": "Ascendis Pharma A/S reported granting 27,030 warrants to certain employees on June 9, 2026, with an exercise price matching the closing share price of US $213.23. The warrants vest over time, with 25% vesting after one year and the remainder over 36 months, subject to continued s", "url": "https://www.stocktitan.net/sec-filings/ASND/6-k-ascendis-pharma-a-s-current-report-foreign-issuer-ecce82934f13.html", "source_name": "Stock Titan", "published_at": "2026-06-10T20:09:46", "published_display": "10 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND) issues 27,030 employee warrants at $213.23 exercise price", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQcHljNkt1Q1VrVldjdFctMWhkYlE1cEpPNzEwdzBiVlVyaG5mNmU5WjJJMHY4dnh5UEpTVHFHM09ERUhCU3lWUGdFNlJSMjkwWHVFMXkxQW00MENRTjBzRUNKMDZNN29VeFNXLS1OeWNLYkxuTWdpRnhLM1pQYlBEbW5wQnNjaE5HZUtDdkdhZUNGQjFoRG81a0NzNFZoVHBnX29qWnJVd1hXT3NsbFV1b3VZRUc4UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQcXhvTkpvQlJfVjF6R2gwWDVjcVd1RHowSk5VaU9mdjJ2dTVQTExnSnNZUmJIR09CMGpkT2Q5V1g4S2V3TnJta05Bb3Y0aEMtN1RuZ2NucE1OSFFveG9jaWNBalJyQkxFTDdkbVlTVkNnR1FrZlZ4alktY1l4ZnZOeHhZLXZyWXFCSnZGODVXTktVSmowV2ZIRw?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness", "summary": "Ascendis Pharma (ASND) has seen its stock price fall recently, raising questions about its valuation. Despite a fair value estimate of $342.08 per share, suggesting it is 38.5% undervalued, this relies on ambitious growth and profitability assumptions for 2029, including \u20ac2.6 bil", "url": "https://finance.yahoo.com/markets/stocks/articles/assessing-ascendis-pharma-asnd-valuation-161039539.html", "source_name": "Market source", "published_at": "2026-06-09T01:38:43", "published_display": "09 Jun 2026 01:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S to Present Latest Data on Endocrinology Rare Disease Programs at ENDO 2026", "summary": "Ascendis Pharma A/S will present new data from its Endocrinology Rare Disease programs at the ENDO 2026 annual meeting in Chicago from June 13-16, 2026. The presentations will include findings on hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency, highlig", "url": "https://www.quiverquant.com/news/Ascendis+Pharma+A%2FS+to+Present+Latest+Data+on+Endocrinology+Rare+Disease+Programs+at+ENDO+2026", "source_name": "Quiver Quantitative", "published_at": "2026-06-08T21:10:05", "published_display": "08 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Asset Management Inc Has $49.90 Million Position in Ascendis Pharma A/S $ASND", "summary": "TD Asset Management Inc reduced its stake in Ascendis Pharma A/S by 21% in Q4, but still holds a significant position of", "url": "https://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-has-4990-million-position-in-ascendis-pharma-as-asnd-2026-06-06/", "source_name": "MarketBeat", "published_at": "2026-06-07T00:39:23", "published_display": "07 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S Stock 12\u2011Month Price Target Raised to $295.6, Implies 40% Upside", "summary": "Ascendis Pharma A/S (ASND) has seen its average 12-month price target increased by analysts to $295.6, up from $293.61. This new target suggests a potential upside of approximately 40% from its June 5 closing price. The consensus among 18 analysts remains a \"Buy\" rating for the s", "url": "https://www.tradingview.com/news/tradingview:5f344a2ad9e0b:0-ascendis-pharma-a-s-stock-12-month-price-target-raised-to-295-6-implies-40-upside/", "source_name": "TradingView", "published_at": "2026-06-06T16:40:12", "published_display": "06 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma reports trial data on achondroplasia treatment", "summary": "Ascendis Pharma A/S announced positive subgroup analysis results from its ApproaCH Trial for achondroplasia treatment, showing sustained growth improvements in children aged 5 and older. The company recently received FDA approval for TransCon CNP (YUVIWELL) and is awaiting Europe", "url": "https://www.investing.com/news/company-news/ascendis-pharma-reports-trial-data-on-achondroplasia-treatment-93CH-4665278", "source_name": "Investing.com", "published_at": "2026-06-04T15:40:00", "published_display": "04 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S", "summary": "The Ascendis Pharma A/S (ASND) analyst forecast page on MLQ.ai provides an overview of its market data, including market capitalization, volume, and various research categories like earnings, financials, and analyst ratings. The page indicates a current consensus of 0 buy, 0 hold", "url": "https://mlq.ai/stocks/v2/ASND/stock-forecast/", "source_name": "MLQ.ai", "published_at": "2026-06-02T23:10:05", "published_display": "02 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND) CFO acquires 100 Ordinary Shares in open-market buy", "summary": "Ascendis Pharma A/S's EVP & Chief Financial Officer, Scott Thomas Smith, purchased 100 Ordinary Shares in an open-market transaction on June 2, 2026, at $219.00 per share. This transaction increases his direct holdings to 4,367 Ordinary Shares. The insider trade shows a positive ", "url": "https://www.stocktitan.net/sec-filings/ASND/form-4-ascendis-pharma-a-s-insider-trading-activity-d5490dd24a58.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:24:46", "published_display": "02 Jun 2026 20:24", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ASND) Movement as an Input in Quant Signal Sets", "summary": "This article provides an AI-generated analysis for Ascendis Pharma A/s (NASDAQ: ASND), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three institutional trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014along with multi-ti", "url": "https://news.stocktradersdaily.com/news_release/132/ASND_Movement_as_an_Input_in_Quant_Signal_Sets_060226064402_1780440242.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-02T18:44:00", "published_display": "02 Jun 2026 18:44", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND) director adds 500 shares in open-market buys", "summary": "Ascendis Pharma A/S director Jean Jacques Bienaime recently purchased 500 Ordinary Shares through three open-market transactions on May 29, 2026, with prices ranging from $222.30 to $223.76 per share. Following these buys, Bienaime directly holds 600 Ordinary Shares of Ascendis P", "url": "https://www.stocktitan.net/sec-filings/ASND/form-4-ascendis-pharma-a-s-insider-trading-activity-08d75786716b.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:10:58", "published_display": "01 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (NASDAQ: ASND) CFO details shares, RSUs and warrant stakes", "summary": "Ascendis Pharma A/S's EVP & Chief Financial Officer, Scott Thomas Smith, has filed an amended Form 3 detailing his equity holdings in the company. The filing indicates he directly owns 4,017 Ordinary Shares, along with Restricted Stock Units (RSUs) covering 9,552, 3,197, and 4,24", "url": "https://www.stocktitan.net/sec-filings/ASND/form-3-a-ascendis-pharma-a-s-amended-initial-statement-of-beneficial--2f3733c9a719.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:10:58", "published_display": "01 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (Nasdaq:ASND) - Stock Analysis", "summary": "Ascendis Pharma (ASND) is analyzed as undervalued by 12.1% with earnings forecasted to grow by 16.93% annually. The company recently became profitable and analysts expect a 33.3% rise in stock price. Recent news includes FDA approval for YUVIWEL, strong commercial traction for ot", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma", "source_name": "Simply Wall Street", "published_at": "2026-05-30T20:09:55", "published_display": "30 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma slides 5.6% as investors digest recent run-up; no single headline catalyst apparent", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQZ1pPbTVEdllLR0JzWXZPRkRRSVdoNzk3MlJZeHdzZ1RoVVY5M0FGcW9JVG1WVmlQbHhZaXhUc0JERWRCQ1R2aGtuVm8tUEgwWDJ5WGcxNVd1WW9sWFgxTnZPRUNtc0s1V3dseG4wdHgyMEliQU5TLV9QZUJlMndWaXY4Y0dNcmFnSVY4R0pHN0FKM1daR1JjZXBjQ3lwcWJTcGU3MDJwZEUwNFdxY3AxS21Oa09sMUY3YkVQOGlWdWNFcXlYYlF4U0NkV0ZFTzU3Q3c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND) director Bienaim\u00e9 buys 400 Ordinary Shares", "summary": "Ascendis Pharma A/S director Jean Jacques Bienaim\u00e9 recently purchased 400 Ordinary Shares of the company in two open-market transactions on May 26, 2026. The shares were bought at weighted average prices of $236.235 and $239.3675 per share, totaling approximately $95,121. This in", "url": "https://www.stocktitan.net/sec-filings/ASND/form-4-ascendis-pharma-a-s-insider-trading-activity-583d5882848d.html", "source_name": "Stock Titan", "published_at": "2026-05-27T19:40:42", "published_display": "27 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (NASDAQ:ASND) Is Posting Healthy Earnings, But It Is Not All Good News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNNzltcmZCSzVxVXd2N1Qxa2VPZzRzckNKcVptQmNNbk8xTGVPMTNYSUxuZjV2eHNnVnl0UzNTeEROT0lBUllTd0tOY3JKVTk3YXBndTBYZnJ5c2lZNFZDeGhLeFdSLXo0NkxtaGltQ1RCYUNuRkpnT0ZxRkVOUUIxRnBwVUZuTmZmRmJiWXl0cjZIXzVud1dRaDgtTHB4YjJvMFE?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings call transcript: Ascendis Pharma Q1 2026 beats EPS forecast By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNMjBFdGZVd2t2WTQtc0ZhNUZ5cU1VOGg5bjlXRGJuRTAxVjVwUXhkeUo3TWNxVUkwTk42cTlDN0p3N2duZ1NPTzZ5RDIzelQySDNYcllhZWYxdHlNSUZaNl9zMWl2Smx2SU5YY0p6MHFaYUFmR1ltMlJTbVNaeWpNUnJiM0FKMlNkZ1lYZVpYTDdCNmZKUlVua0pwUXo5a012LWNFaUpETWhGUFdnTktGWlhFcXJlNVhJZEEwODRPemtRRUNXWjlB?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis will post quarterly results before markets open May 7", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNVGFldml0el9MV0l2dWhWU0NwNVpUV1dXZmljS2w2TVJsbUlxdzdMUnZXcjc0ZC1FUk9ILUxYSGFkUzNpZVJvYnExQlRIcmtMMFVMMXB3T2x3WnM3LUpvbEo4b3N3bEpVM2FNODhveldUbnQxamx2MnY3cEVNRnczMEsyVU92RzQ0ejNEdmNMY3JKUjQ1OU1lclhGLTYxWkdOdGltbGlKRlFjTlhXTER0S2dJSllEMEp3eXJXX1NjSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ascendis Pharma slides as investors digest share-structure switch and convertible-note redemption | ASND Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQaW9YX0Y1ZzZzMjM0dFp4T2ZkZEU1WkJYODNKZ0poaHlpY0NhakNJdDlUdnB1YzY0RGx1WVM4MlBuazU5aWFvZ3RXOGllVW41ZkVZT3N0S3g4RElONUlTREVYbmJRSGVVWktieWV1U05xUXRkWWU1YXNNOG0teVN1SHZlVkRJQnRsY010alotN3B2cFVYT2dRa0lGbDJpZGxLMy1Ec2FnSjZJa3pEY3BYcWZfZ053ZjE5UG9XeGhUeXlFSWNhdWxQNm1n?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Ascendis Pharma (ASND) to List Ordinary Shares Directly on Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNUG43b3EyVWtWNDZ3eWJDQURLdkhlTU5FZHg1YnZ0M1JiODdacWwycDFDZDlxajBjcnJkNXpGcE9kUXdmcWlOQ1lwU1hIcUNRQXlzc25WaTB2aFk1Y2NYeDVSMFptVnBhWkRqTWRJX1AzdEthNTV5WXBTLVo0WDZYVHhVNFFfUzRSVm5KQThBQ0Qta2pSSXNiUTJYZHJUekNT?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis reports arm span, spinal improvements in achondroplasia trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPSGpxdXZMbGpMQmk0ZXhPWjRSSGY4VlRKN3dVNXRQcDZtMkw0eDhWN3dieE5pVmROSE51Z3drd3hPRjlScGxvNDdQVllBaHVpOGtidm11MWQ4SzNhMmJVaFlhV2lfcDg0M3FVNXUxMEJvVGFvMkVQOU54VW1lT3pic0d5Vk5RemlhVWRWd09ZUWphUTVZeXBkRkVqU0lkYzNIS1A2MnVzQlRxNkpxQUd1VFJNU1EzUjZ2WEptOERRTi1YV0lt?oc=5", "source_name": "Investing.com", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma\u2019s YUVIWEL gains orphan drug exclusivity in U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPZHRkbkhzWkZWUmRkanVoVm5nRXJJUjhpZDZmU3Z4WjdfT240MHBnWmZ3TjY5dGJqaGlGVFRfdTFod3hlZGZNc2loWUhhbVBFVnJSRzZhcDRwUk0ya3ptM19HUTVMVDJ6WUJHMXB4NnUzalROYVFzSEpINjkwMUNDZkl0VnlzUW5rNnZRUnpLM1puNEt0Y1dhRkNmQVZmVXQ3WVgtZTBONzRVcmV4RUcxNmpVWm80TDdh?oc=5", "source_name": "Investing.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "BofA raises Ascendis Pharma stock price target on Yuviwel pricing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWTJ2eGhlRkM5dkZ2bk9teG52eVdrdjRwdko1UkktRUdGRy0tV0lzT3E4WjdTb1NMRmZKTDcyQ2dMaHJWQkxzTDhvMWVlUE1iNW10SkJFbmtKQ1hNamRJTHZZTk53eFkyVU1LeC1zdVYzRWFOWVNDelRHVFRZajdfbUxSOElNZG1YUUdwREtSbDgxX085Rkh2WHVfbWRLbVUzNlZjYVh2NTNQWVZPSUVfQ1h6cG80Y1RfZGlJR3Q2YWtXSDA?oc=5", "source_name": "Investing.com", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel raises Ascendis Pharma stock price target on Yuviwel approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQN3owWHlsQV9NX1h1ZW9teVlRQW5rSC15b21waVRZN2RRcEZ4UnAwTjUxMnZKbzNQV3BqaTJ5NFNlN0h1MHg2OEJTeUJfZ3IwZG13X2ozbDBxamJIUmxBLUpvcm5vUS1nNE1yaGtIcmlxdmRMYzRoUXVtMUp4QmxoM2JEamxRSTh5T2NwVmhpTXliTnJGX0M1dWFjTmdsOURwVjZ2ZFlSb3dNRUUxOVpQb2ZDcmFVQjlHSHJvSlpGMGJEbmpvdElR?oc=5", "source_name": "Investing.com", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma AS earnings missed by \u20ac0.40, revenue fell short of estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOZDFTY3pMVlgtbkw1SjlsbDVDMFJ5NEpHbXhDNVUxLS0yZHVDNVdnUW45V1lHSkdFc3hZZFNGb3BscEowOWVJcDY4NUJ5UTdCcjVxVV92UDRtVENuWEhfY0ZTQlFsdUd5X1lmVk9aeFZrbnMyVzgtMFdxOGRjb3QzOTRvZUxkY0toWnVjM2VhTVktNUVSQXU4MVBjTzJMSWdfX0R1WDRNOFdINXU2MS1ZbklfMmpjUFlpWEVpOVl3?oc=5", "source_name": "Investing.com", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Ascendis Pharma Q4 2025 misses EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxONGw4ZHFKeHd2YTRvNTFxSzRKeEFwVjRTZ240bm9UR2UzS3kzWFRvcFJIaTJLZ1VhbTZNNFVtdVZzY093T2UwVEk2aGlYVGRSQ0ozQ0FsVjJQVF82cEIwVDVJUXJqTXBWbmNnclpXbTAzeHNTRXFDVUtsWm5lUU5fdll4MEEyWV94andYQWJkY3NyLXlsVkZpdFBEdUxyUjJmVmUxdEFYaXhoRDN0azJKRHl2LVpSRTdNMmpjOGZsMDJSSjdmdEdz?oc=5", "source_name": "Investing.com", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQa0RtdXJLaTF6TFZNQzgtcnJmaDdndlVqUGc0Q1BPLWNTVks2eTFONmdma1BZa0Z3NWxwM1dGZnp3NjhQRVdsU1EwTmFuODdsSmg0MTZtbGZtNXpyMlFGYlBGbHlyOHR5MDVmaU12MXFYa2dCRU4yeEx0YnEtMlg1cHdsUWRnMF9CZXE3OHpn?oc=5", "source_name": "Market source", "published_at": "2026-01-25T08:00:00+00:00", "published_display": "25 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "TD Cowen maintains Buy rating on Ascendis Pharma stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNX0JveWhzYVRDUmhDZW5LeHFXS1JkcWlzbmdQZFRNdHJuTUFhblJmVHpnYktkbjhSVTNtRS15bU16di1rRjBQM3NhNnVpWE16cFJranFtWEdTNHFWR3RMbEdZbGZibmlPbzJCc1dfMHVveURDZWNLc3ZmTHR0ZDNUUTNRdjdWVU5VR25VVTlxd01DQ0xlcUVzYlI2c3BJeFVMMWlVdnV0RHpzZWdGNG5JVG4tTWk?oc=5", "source_name": "Investing.com", "published_at": "2025-06-10T07:00:00+00:00", "published_display": "10 Jun 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs retains Buy on Ascendis Pharma shares, cites legal action", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNeWRKSUtUaDFtVFEyNlNLVzBSdzZwNGxVUHFvcnJCUWVTU296SllsS29IRWlxVGhFQnBNOGt5ZFhReWNzdjRGMnNzTnIyR2phSExmX2ZWYklnVWZDTkxHa2FtVDFfcFp4ZVZqbFJUNkRibmlCZGlFeHRqLU9fblNsb3c0Um9GMjFqR2RMV3VxSlg2eFlGYjJBbkduNjktODRLWnU2RWZub1ljVHpOeU1EWEItMHNJblhWLThRN0xxdjJvRXcxclNaWDB3?oc=5", "source_name": "Investing.com", "published_at": "2025-01-15T08:00:00+00:00", "published_display": "15 Jan 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating", "summary": "J.P. Morgan has reiterated its Buy rating on Ascendis Pharma A/S (ASND.US) stock. The analyst maintained a price target of $170.00, suggesting potential upside for investors.", "url": "https://news.futunn.com/en/post/74780172/jp-morgan-maintains-ascendis-pharma-a-s-asndus-with-buy", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-06-19T19:09:11", "published_display": "19 Jun 2026 19:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S (ASND) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Ascendis Pharma A/S (ASND) currently has an earnings forecast score of 8.95 and an average price target of $254.00 from 20 analysts, with a \"Strong Buy\" rating. Analysts expect the company's next quarter revenue to be $384.76M and EPS to be $1.70, a significant improvement from t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-asnd/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:09:35", "published_display": "18 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (NASDAQ: ASND) nets $187.5M from FDA PRV sale", "summary": "Ascendis Pharma (NASDAQ: ASND) announced the sale of its U.S. Rare Pediatric Disease Priority Review Voucher (PRV) for $187.5 million in cash to an undisclosed buyer. This PRV was granted following the FDA approval of YUVIWEL\u00ae (navepegritide) in February 2026. The transaction is ", "url": "https://www.stocktitan.net/sec-filings/ASND/6-k-ascendis-pharma-a-s-current-report-foreign-issuer-ed53c0783f11.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:35", "published_display": "17 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $326", "summary": "Wells Fargo has reiterated its Buy rating for Ascendis Pharma A/S (ASND.US) and maintained its price target of $326. This indicates the firm's continued confidence in the company's stock performance.", "url": "https://www.moomoo.com/news/post/71663488/wells-fargo-maintains-ascendis-pharma-a-s-asndus-with-buy", "source_name": "Moomoo", "published_at": "2026-06-17T16:10:01", "published_display": "17 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S (ASND) Stock Analysis: A Biotech Powerhouse with 36.97% Potential Upside", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxObXllQTZhNmhsWUFVNDZlSjBsc2t5OWswVjYxTEd1alBOb3BpSUF2eHMzTDlLNUhpM1JfUXZJcmtaTU5ycjBDeTRQTEV0dndMZnBnWFJEalB3RTFpVzZsRGNVb1B3S2cwbEF0OGRjTlF2WmVIQ0ZWZk1weUR0S2R1YTkzb29rZTl5S3hMSmNRQjRvNXJNX1hQejFoQVZ6YnU5TVBBRkduNnJkZEJkRGdEZEZUdE13S0x6clNJWVRvcFI1emVvZFZzVklsdW5xV1ZGYlRGUw?oc=5", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-15T09:15:40+00:00", "published_display": "15 Jun 2026 09:15", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Long-term TransCon PTH data from Ascendis Pharma (ASND) show sustained benefits", "summary": "Ascendis Pharma reported positive 3.5-year data from its Phase 3 PaTHway Trial of TransCon PTH (palopegteriparatide) for adults with hypoparathyroidism. The study demonstrated sustained efficacy, safety, and improvements in quality of life and key biochemical markers. Patients ma", "url": "https://www.stocktitan.net/sec-filings/ASND/6-k-ascendis-pharma-a-s-current-report-foreign-issuer-9306be65471e.html", "source_name": "Stock Titan", "published_at": "2026-06-15T10:09:29", "published_display": "15 Jun 2026 10:09", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - Slideshow", "summary": "Ascendis Pharma A/S (ASND) presented a slideshow at the Endocrine Society's Annual Meeting (ENDO 2026). The company published a slide deck in conjunction with this event. This article was prepared by Seeking Alpha's transcripts team.", "url": "https://seekingalpha.com/article/4914923-ascendis-pharma-a-s-asnd-presents-at-endocrine-societys-annual-meeting-endo-2026-slideshow", "source_name": "Seeking Alpha", "published_at": "2026-06-15T06:09:29", "published_display": "15 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ASND) Risk Channels and Responsive Allocation", "summary": "This article analyzes Ascendis Pharma A/s (NASDAQ: ASND) using AI models, identifying a positive near-term sentiment while noting potential mid-term weakness within a long-term strong context. It outlines specific institutional trading strategies including position trading, momen", "url": "https://news.stocktradersdaily.com/news_release/98/ASND_Risk_Channels_and_Responsive_Allocation_061326081402_1781396042.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-13T20:38:43", "published_display": "13 Jun 2026 20:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma Reports Sustained Efficacy and Safety of TransCon PTH in Phase 3 PaTHway Trial for Hypoparathyroidism After Three and a Half Years", "summary": "Ascendis Pharma announced positive long-term results from its Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The treatment demonstrated sustained efficacy and safety over three and a half years, showing significant improvements in ", "url": "https://www.quiverquant.com/news/Ascendis+Pharma+Reports+Sustained+Efficacy+and+Safety+of+TransCon+PTH+in+Phase+3+PaTHway+Trial+for+Hypoparathyroidism+After+Three+and+a+Half+Years", "source_name": "Quiver Quantitative", "published_at": "2026-06-13T20:10:00", "published_display": "13 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hormone shot helps hypoparathyroidism patients cut daily calcium and vitamin D", "summary": "Ascendis Pharma announced positive long-term Phase 3 data for their drug TransCon PTH, showing sustained efficacy and safety for adults with hypoparathyroidism. The treatment helped 86% of patients meet a multi-component endpoint and allowed 100% to achieve independence from acti", "url": "https://www.stocktitan.net/news/ASND/phase-3-data-show-trans-con-pth-replicated-systemic-actions-of-umpzb1yzp30n.html", "source_name": "Stock Titan", "published_at": "2026-06-13T19:38:43", "published_display": "13 Jun 2026 19:38", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phase 3 Data Show TransCon\u00ae PTH Replicated Systemic Actions", "summary": "Ascendis Pharma A/S announced Week 182 data from its Phase 3 PaTHway Trial, demonstrating that TransCon PTH (palopegteriparatide) provided sustained efficacy and safety in adults with hypoparathyroidism over three and a half years. The treatment replicated the systemic actions of", "url": "https://www.globenewswire.com/news-release/2026/06/13/3311416/0/en/phase-3-data-show-transcon-pth-replicated-systemic-actions-of-endogenous-pth-through-week-182-in-adults-with-hypoparathyroidism.html", "source_name": "GlobeNewswire", "published_at": "2026-06-13T16:00:00", "published_display": "13 Jun 2026 16:00", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Ascendis Pharma Stock Gaining Friday? - Ascendis Pharma (NASDAQ:ASND)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPSV9USFhQMV9rV0YtYU1NSlhQc3BkSFphaEVTR0E4bmlhbEdEdldrdlRWeXlIZzNEZThxS3IwOHhBUUJzUDVwMzI4c2hDclpGVFVOUkNPR3plVzJ6VmVoT1FVaGFJWXdqa1dBYTRCUHBfbUtsTTlWRmVWWWF4MkNxN2NGTktQemhfbERtM2ZpUDBJQ2ZvNGxWa01xT2xkYWxabmc?oc=5", "source_name": "Benzinga", "published_at": "2026-06-12T16:29:22+00:00", "published_display": "12 Jun 2026 16:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Ascendis Pharma Stock Gaining Friday?", "summary": "Ascendis Pharma A/S (NASDAQ: ASND) stock rose Friday after the company reported positive five-year results from its Phase 2 PaTH Forward trial for TransCon PTH (palopegteriparatide), a treatment for hypoparathyroidism. The trial demonstrated sustained efficacy and safety, with mo", "url": "https://www.sahmcapital.com/news/content/why-is-ascendis-pharma-stock-gaining-friday-2026-06-12", "source_name": "Sahm", "published_at": "2026-06-12T13:39:40", "published_display": "12 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma Says TransCon PTH Shows Sustained Efficacy at 5 Years", "summary": "Ascendis Pharma announced that its investigational drug, TransCon PTH, demonstrated sustained efficacy and safety for up to 5 years in patients with hypoparathyroidism. Data from the Phase 2 PaTH Forward study showed that a majority of patients maintained independence from conven", "url": "https://www.moomoo.com/news/post/71413605/ascendis-pharma-says-transcon-pth-shows-sustained-efficacy-at-5?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-12T13:09:38", "published_display": "12 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 86, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five-year TransCon PTH trial results reported by Ascendis Pharma (ASND)", "summary": "Ascendis Pharma A/S reported positive 5-year (Week 266) results from its Phase 2 PaTH Forward Trial of TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The trial demonstrated sustained efficacy and safety, replicating the systemic actions of natural parathyro", "url": "https://www.stocktitan.net/sec-filings/ASND/6-k-ascendis-pharma-a-s-current-report-foreign-issuer-dfda8d37897c.html", "source_name": "Stock Titan", "published_at": "2026-06-12T09:40:13", "published_display": "12 Jun 2026 09:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis boasts of long-term Yorvipath data for hypoparathyroidism", "summary": "Ascendis Pharma announced new long-term data from a Phase 2 trial of its hypoparathyroidism treatment, Yorvipath (palopegteriparatide). The data indicate sustained efficacy over five years, with the hormone replacement therapy showing a beneficial impact on target organs.", "url": "https://seekingalpha.com/news/4602771-ascendis-boasts-long-term-yorvipath-data-hypoparathyroidism", "source_name": "Seeking Alpha", "published_at": "2026-06-11T20:39:23", "published_display": "11 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5-Year Phase 2 Data Show TransCon\u00ae PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism", "summary": "Ascendis Pharma announced 5-year Phase 2 data from its PaTH Forward Trial, demonstrating sustained efficacy and safety of TransCon PTH in adults with hypoparathyroidism. The treatment replicated endogenous PTH actions, showing benefits in kidney function, bone mineral density, an", "url": "https://www.globenewswire.com/news-release/2026/06/11/3310783/0/en/5-Year-Phase-2-Data-Show-TransCon-PTH-Replicated-Systemic-Actions-of-Endogenous-PTH-in-Adults-with-Hypoparathyroidism.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T19:39:23", "published_display": "11 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5-year trial: drug frees most hypoparathyroidism patients from supplements", "summary": "Ascendis Pharma reported positive 5-year Phase 2 data for TransCon PTH in adults with hypoparathyroidism, showing sustained efficacy and safety. The drug normalized calcium levels, improved kidney function, and enhanced quality of life, with 82% of patients meeting the multi-comp", "url": "https://www.stocktitan.net/news/ASND/5-year-phase-2-data-show-trans-con-pth-replicated-systemic-actions-cbbltuk82qs8.html", "source_name": "Stock Titan", "published_at": "2026-06-11T19:39:23", "published_display": "11 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma grants 27,030 employee warrants at $213.23 per share", "summary": "Ascendis Pharma's board of directors has issued 27,030 warrants to employees, allowing them to subscribe for shares at $213.23 each. The warrants will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over the subsequent three years, cont", "url": "https://www.investing.com/news/sec-filings/ascendis-pharma-grants-27030-employee-warrants-at-21323-per-share-93CH-4736124", "source_name": "Investing.com", "published_at": "2026-06-11T00:09:46", "published_display": "11 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[6-K] Ascendis Pharma A/S Current Report (Foreign Issuer) | ASND SEC Filing - Form 6-K", "summary": "Ascendis Pharma A/S reported granting 27,030 warrants to certain employees on June 9, 2026, with an exercise price matching the closing share price of US $213.23. The warrants vest over time, with 25% vesting after one year and the remainder over 36 months, subject to continued s", "url": "https://www.stocktitan.net/sec-filings/ASND/6-k-ascendis-pharma-a-s-current-report-foreign-issuer-ecce82934f13.html", "source_name": "Stock Titan", "published_at": "2026-06-10T20:09:46", "published_display": "10 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND) issues 27,030 employee warrants at $213.23 exercise price", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxQcHljNkt1Q1VrVldjdFctMWhkYlE1cEpPNzEwdzBiVlVyaG5mNmU5WjJJMHY4dnh5UEpTVHFHM09ERUhCU3lWUGdFNlJSMjkwWHVFMXkxQW00MENRTjBzRUNKMDZNN29VeFNXLS1OeWNLYkxuTWdpRnhLM1pQYlBEbW5wQnNjaE5HZUtDdkdhZUNGQjFoRG81a0NzNFZoVHBnX29qWnJVd1hXT3NsbFV1b3VZRUc4UQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND):10 Most Profitable Growth Stocks to Buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQcXhvTkpvQlJfVjF6R2gwWDVjcVd1RHowSk5VaU9mdjJ2dTVQTExnSnNZUmJIR09CMGpkT2Q5V1g4S2V3TnJta05Bb3Y0aEMtN1RuZ2NucE1OSFFveG9jaWNBalJyQkxFTDdkbVlTVkNnR1FrZlZ4alktY1l4ZnZOeHhZLXZyWXFCSnZGODVXTktVSmowV2ZIRw?oc=5", "source_name": "Market source", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Weakness", "summary": "Ascendis Pharma (ASND) has seen its stock price fall recently, raising questions about its valuation. Despite a fair value estimate of $342.08 per share, suggesting it is 38.5% undervalued, this relies on ambitious growth and profitability assumptions for 2029, including \u20ac2.6 bil", "url": "https://finance.yahoo.com/markets/stocks/articles/assessing-ascendis-pharma-asnd-valuation-161039539.html", "source_name": "Market source", "published_at": "2026-06-09T01:38:43", "published_display": "09 Jun 2026 01:38", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S to Present Latest Data on Endocrinology Rare Disease Programs at ENDO 2026", "summary": "Ascendis Pharma A/S will present new data from its Endocrinology Rare Disease programs at the ENDO 2026 annual meeting in Chicago from June 13-16, 2026. The presentations will include findings on hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency, highlig", "url": "https://www.quiverquant.com/news/Ascendis+Pharma+A%2FS+to+Present+Latest+Data+on+Endocrinology+Rare+Disease+Programs+at+ENDO+2026", "source_name": "Quiver Quantitative", "published_at": "2026-06-08T21:10:05", "published_display": "08 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Asset Management Inc Has $49.90 Million Position in Ascendis Pharma A/S $ASND", "summary": "TD Asset Management Inc reduced its stake in Ascendis Pharma A/S by 21% in Q4, but still holds a significant position of", "url": "https://www.marketbeat.com/instant-alerts/filing-td-asset-management-inc-has-4990-million-position-in-ascendis-pharma-as-asnd-2026-06-06/", "source_name": "MarketBeat", "published_at": "2026-06-07T00:39:23", "published_display": "07 Jun 2026 00:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S Stock 12\u2011Month Price Target Raised to $295.6, Implies 40% Upside", "summary": "Ascendis Pharma A/S (ASND) has seen its average 12-month price target increased by analysts to $295.6, up from $293.61. This new target suggests a potential upside of approximately 40% from its June 5 closing price. The consensus among 18 analysts remains a \"Buy\" rating for the s", "url": "https://www.tradingview.com/news/tradingview:5f344a2ad9e0b:0-ascendis-pharma-a-s-stock-12-month-price-target-raised-to-295-6-implies-40-upside/", "source_name": "TradingView", "published_at": "2026-06-06T16:40:12", "published_display": "06 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma reports trial data on achondroplasia treatment", "summary": "Ascendis Pharma A/S announced positive subgroup analysis results from its ApproaCH Trial for achondroplasia treatment, showing sustained growth improvements in children aged 5 and older. The company recently received FDA approval for TransCon CNP (YUVIWELL) and is awaiting Europe", "url": "https://www.investing.com/news/company-news/ascendis-pharma-reports-trial-data-on-achondroplasia-treatment-93CH-4665278", "source_name": "Investing.com", "published_at": "2026-06-04T15:40:00", "published_display": "04 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma A/S", "summary": "The Ascendis Pharma A/S (ASND) analyst forecast page on MLQ.ai provides an overview of its market data, including market capitalization, volume, and various research categories like earnings, financials, and analyst ratings. The page indicates a current consensus of 0 buy, 0 hold", "url": "https://mlq.ai/stocks/v2/ASND/stock-forecast/", "source_name": "MLQ.ai", "published_at": "2026-06-02T23:10:05", "published_display": "02 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND) CFO acquires 100 Ordinary Shares in open-market buy", "summary": "Ascendis Pharma A/S's EVP & Chief Financial Officer, Scott Thomas Smith, purchased 100 Ordinary Shares in an open-market transaction on June 2, 2026, at $219.00 per share. This transaction increases his direct holdings to 4,367 Ordinary Shares. The insider trade shows a positive ", "url": "https://www.stocktitan.net/sec-filings/ASND/form-4-ascendis-pharma-a-s-insider-trading-activity-d5490dd24a58.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:24:46", "published_display": "02 Jun 2026 20:24", "sentiment": "positive", "sentiment_pct": 68, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "(ASND) Movement as an Input in Quant Signal Sets", "summary": "This article provides an AI-generated analysis for Ascendis Pharma A/s (NASDAQ: ASND), highlighting weak near and mid-term sentiment but a strong long-term outlook. It details three institutional trading strategies\u2014Position, Momentum Breakout, and Risk Hedging\u2014along with multi-ti", "url": "https://news.stocktradersdaily.com/news_release/132/ASND_Movement_as_an_Input_in_Quant_Signal_Sets_060226064402_1780440242.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-02T18:44:00", "published_display": "02 Jun 2026 18:44", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND) director adds 500 shares in open-market buys", "summary": "Ascendis Pharma A/S director Jean Jacques Bienaime recently purchased 500 Ordinary Shares through three open-market transactions on May 29, 2026, with prices ranging from $222.30 to $223.76 per share. Following these buys, Bienaime directly holds 600 Ordinary Shares of Ascendis P", "url": "https://www.stocktitan.net/sec-filings/ASND/form-4-ascendis-pharma-a-s-insider-trading-activity-08d75786716b.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:10:58", "published_display": "01 Jun 2026 20:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (NASDAQ: ASND) CFO details shares, RSUs and warrant stakes", "summary": "Ascendis Pharma A/S's EVP & Chief Financial Officer, Scott Thomas Smith, has filed an amended Form 3 detailing his equity holdings in the company. The filing indicates he directly owns 4,017 Ordinary Shares, along with Restricted Stock Units (RSUs) covering 9,552, 3,197, and 4,24", "url": "https://www.stocktitan.net/sec-filings/ASND/form-3-a-ascendis-pharma-a-s-amended-initial-statement-of-beneficial--2f3733c9a719.html", "source_name": "Stock Titan", "published_at": "2026-06-01T20:10:58", "published_display": "01 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (Nasdaq:ASND) - Stock Analysis", "summary": "Ascendis Pharma (ASND) is analyzed as undervalued by 12.1% with earnings forecasted to grow by 16.93% annually. The company recently became profitable and analysts expect a 33.3% rise in stock price. Recent news includes FDA approval for YUVIWEL, strong commercial traction for ot", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-asnd/ascendis-pharma", "source_name": "Simply Wall Street", "published_at": "2026-05-30T20:09:55", "published_display": "30 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma slides 5.6% as investors digest recent run-up; no single headline catalyst apparent", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQZ1pPbTVEdllLR0JzWXZPRkRRSVdoNzk3MlJZeHdzZ1RoVVY5M0FGcW9JVG1WVmlQbHhZaXhUc0JERWRCQ1R2aGtuVm8tUEgwWDJ5WGcxNVd1WW9sWFgxTnZPRUNtc0s1V3dseG4wdHgyMEliQU5TLV9QZUJlMndWaXY4Y0dNcmFnSVY4R0pHN0FKM1daR1JjZXBjQ3lwcWJTcGU3MDJwZEUwNFdxY3AxS21Oa09sMUY3YkVQOGlWdWNFcXlYYlF4U0NkV0ZFTzU3Q3c?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND) director Bienaim\u00e9 buys 400 Ordinary Shares", "summary": "Ascendis Pharma A/S director Jean Jacques Bienaim\u00e9 recently purchased 400 Ordinary Shares of the company in two open-market transactions on May 26, 2026. The shares were bought at weighted average prices of $236.235 and $239.3675 per share, totaling approximately $95,121. This in", "url": "https://www.stocktitan.net/sec-filings/ASND/form-4-ascendis-pharma-a-s-insider-trading-activity-583d5882848d.html", "source_name": "Stock Titan", "published_at": "2026-05-27T19:40:42", "published_display": "27 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (NASDAQ:ASND) Is Posting Healthy Earnings, But It Is Not All Good News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNNzltcmZCSzVxVXd2N1Qxa2VPZzRzckNKcVptQmNNbk8xTGVPMTNYSUxuZjV2eHNnVnl0UzNTeEROT0lBUllTd0tOY3JKVTk3YXBndTBYZnJ5c2lZNFZDeGhLeFdSLXo0NkxtaGltQ1RCYUNuRkpnT0ZxRkVOUUIxRnBwVUZuTmZmRmJiWXl0cjZIXzVud1dRaDgtTHB4YjJvMFE?oc=5", "source_name": "Market source", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Ascendis Pharma Q1 2026 beats EPS forecast By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNMjBFdGZVd2t2WTQtc0ZhNUZ5cU1VOGg5bjlXRGJuRTAxVjVwUXhkeUo3TWNxVUkwTk42cTlDN0p3N2duZ1NPTzZ5RDIzelQySDNYcllhZWYxdHlNSUZaNl9zMWl2Smx2SU5YY0p6MHFaYUFmR1ltMlJTbVNaeWpNUnJiM0FKMlNkZ1lYZVpYTDdCNmZKUlVua0pwUXo5a012LWNFaUpETWhGUFdnTktGWlhFcXJlNVhJZEEwODRPemtRRUNXWjlB?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis will post quarterly results before markets open May 7", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNVGFldml0el9MV0l2dWhWU0NwNVpUV1dXZmljS2w2TVJsbUlxdzdMUnZXcjc0ZC1FUk9ILUxYSGFkUzNpZVJvYnExQlRIcmtMMFVMMXB3T2x3WnM3LUpvbEo4b3N3bEpVM2FNODhveldUbnQxamx2MnY3cEVNRnczMEsyVU92RzQ0ejNEdmNMY3JKUjQ1OU1lclhGLTYxWkdOdGltbGlKRlFjTlhXTER0S2dJSllEMEp3eXJXX1NjSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma slides as investors digest share-structure switch and convertible-note redemption | ASND Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxQaW9YX0Y1ZzZzMjM0dFp4T2ZkZEU1WkJYODNKZ0poaHlpY0NhakNJdDlUdnB1YzY0RGx1WVM4MlBuazU5aWFvZ3RXOGllVW41ZkVZT3N0S3g4RElONUlTREVYbmJRSGVVWktieWV1U05xUXRkWWU1YXNNOG0teVN1SHZlVkRJQnRsY010alotN3B2cFVYT2dRa0lGbDJpZGxLMy1Ec2FnSjZJa3pEY3BYcWZfZ053ZjE5UG9XeGhUeXlFSWNhdWxQNm1n?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma (ASND) to List Ordinary Shares Directly on Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNUG43b3EyVWtWNDZ3eWJDQURLdkhlTU5FZHg1YnZ0M1JiODdacWwycDFDZDlxajBjcnJkNXpGcE9kUXdmcWlOQ1lwU1hIcUNRQXlzc25WaTB2aFk1Y2NYeDVSMFptVnBhWkRqTWRJX1AzdEthNTV5WXBTLVo0WDZYVHhVNFFfUzRSVm5KQThBQ0Qta2pSSXNiUTJYZHJUekNT?oc=5", "source_name": "Market source", "published_at": "2026-04-12T07:00:00+00:00", "published_display": "12 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis reports arm span, spinal improvements in achondroplasia trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPSGpxdXZMbGpMQmk0ZXhPWjRSSGY4VlRKN3dVNXRQcDZtMkw0eDhWN3dieE5pVmROSE51Z3drd3hPRjlScGxvNDdQVllBaHVpOGtidm11MWQ4SzNhMmJVaFlhV2lfcDg0M3FVNXUxMEJvVGFvMkVQOU54VW1lT3pic0d5Vk5RemlhVWRWd09ZUWphUTVZeXBkRkVqU0lkYzNIS1A2MnVzQlRxNkpxQUd1VFJNU1EzUjZ2WEptOERRTi1YV0lt?oc=5", "source_name": "Investing.com", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma\u2019s YUVIWEL gains orphan drug exclusivity in U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxPZHRkbkhzWkZWUmRkanVoVm5nRXJJUjhpZDZmU3Z4WjdfT240MHBnWmZ3TjY5dGJqaGlGVFRfdTFod3hlZGZNc2loWUhhbVBFVnJSRzZhcDRwUk0ya3ptM19HUTVMVDJ6WUJHMXB4NnUzalROYVFzSEpINjkwMUNDZkl0VnlzUW5rNnZRUnpLM1puNEt0Y1dhRkNmQVZmVXQ3WVgtZTBONzRVcmV4RUcxNmpVWm80TDdh?oc=5", "source_name": "Investing.com", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BofA raises Ascendis Pharma stock price target on Yuviwel pricing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWTJ2eGhlRkM5dkZ2bk9teG52eVdrdjRwdko1UkktRUdGRy0tV0lzT3E4WjdTb1NMRmZKTDcyQ2dMaHJWQkxzTDhvMWVlUE1iNW10SkJFbmtKQ1hNamRJTHZZTk53eFkyVU1LeC1zdVYzRWFOWVNDelRHVFRZajdfbUxSOElNZG1YUUdwREtSbDgxX085Rkh2WHVfbWRLbVUzNlZjYVh2NTNQWVZPSUVfQ1h6cG80Y1RfZGlJR3Q2YWtXSDA?oc=5", "source_name": "Investing.com", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel raises Ascendis Pharma stock price target on Yuviwel approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxQN3owWHlsQV9NX1h1ZW9teVlRQW5rSC15b21waVRZN2RRcEZ4UnAwTjUxMnZKbzNQV3BqaTJ5NFNlN0h1MHg2OEJTeUJfZ3IwZG13X2ozbDBxamJIUmxBLUpvcm5vUS1nNE1yaGtIcmlxdmRMYzRoUXVtMUp4QmxoM2JEamxRSTh5T2NwVmhpTXliTnJGX0M1dWFjTmdsOURwVjZ2ZFlSb3dNRUUxOVpQb2ZDcmFVQjlHSHJvSlpGMGJEbmpvdElR?oc=5", "source_name": "Investing.com", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Ascendis Pharma AS earnings missed by \u20ac0.40, revenue fell short of estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOZDFTY3pMVlgtbkw1SjlsbDVDMFJ5NEpHbXhDNVUxLS0yZHVDNVdnUW45V1lHSkdFc3hZZFNGb3BscEowOWVJcDY4NUJ5UTdCcjVxVV92UDRtVENuWEhfY0ZTQlFsdUd5X1lmVk9aeFZrbnMyVzgtMFdxOGRjb3QzOTRvZUxkY0toWnVjM2VhTVktNUVSQXU4MVBjTzJMSWdfX0R1WDRNOFdINXU2MS1ZbklfMmpjUFlpWEVpOVl3?oc=5", "source_name": "Investing.com", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Ascendis Pharma Q4 2025 misses EPS expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxONGw4ZHFKeHd2YTRvNTFxSzRKeEFwVjRTZ240bm9UR2UzS3kzWFRvcFJIaTJLZ1VhbTZNNFVtdVZzY093T2UwVEk2aGlYVGRSQ0ozQ0FsVjJQVF82cEIwVDVJUXJqTXBWbmNnclpXbTAzeHNTRXFDVUtsWm5lUU5fdll4MEEyWV94andYQWJkY3NyLXlsVkZpdFBEdUxyUjJmVmUxdEFYaXhoRDN0azJKRHl2LVpSRTdNMmpjOGZsMDJSSjdmdEdz?oc=5", "source_name": "Investing.com", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxQa0RtdXJLaTF6TFZNQzgtcnJmaDdndlVqUGc0Q1BPLWNTVks2eTFONmdma1BZa0Z3NWxwM1dGZnp3NjhQRVdsU1EwTmFuODdsSmg0MTZtbGZtNXpyMlFGYlBGbHlyOHR5MDVmaU12MXFYa2dCRU4yeEx0YnEtMlg1cHdsUWRnMF9CZXE3OHpn?oc=5", "source_name": "Market source", "published_at": "2026-01-25T08:00:00+00:00", "published_display": "25 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TD Cowen maintains Buy rating on Ascendis Pharma stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNX0JveWhzYVRDUmhDZW5LeHFXS1JkcWlzbmdQZFRNdHJuTUFhblJmVHpnYktkbjhSVTNtRS15bU16di1rRjBQM3NhNnVpWE16cFJranFtWEdTNHFWR3RMbEdZbGZibmlPbzJCc1dfMHVveURDZWNLc3ZmTHR0ZDNUUTNRdjdWVU5VR25VVTlxd01DQ0xlcUVzYlI2c3BJeFVMMWlVdnV0RHpzZWdGNG5JVG4tTWk?oc=5", "source_name": "Investing.com", "published_at": "2025-06-10T07:00:00+00:00", "published_display": "10 Jun 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs retains Buy on Ascendis Pharma shares, cites legal action", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNeWRKSUtUaDFtVFEyNlNLVzBSdzZwNGxVUHFvcnJCUWVTU296SllsS29IRWlxVGhFQnBNOGt5ZFhReWNzdjRGMnNzTnIyR2phSExmX2ZWYklnVWZDTkxHa2FtVDFfcFp4ZVZqbFJUNkRibmlCZGlFeHRqLU9fblNsb3c0Um9GMjFqR2RMV3VxSlg2eFlGYjJBbkduNjktODRLWnU2RWZub1ljVHpOeU1EWEItMHNJblhWLThRN0xxdjJvRXcxclNaWDB3?oc=5", "source_name": "Investing.com", "published_at": "2025-01-15T08:00:00+00:00", "published_display": "15 Jan 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 57, "sentiment_summary": {"positive": 33, "negative": 4, "neutral": 20, "score": 65, "total": 57, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 9.49, "count": 19}, {"event": "analyst", "label": "Analyst action", "weight": 4.2, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 33, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 230.83, "latest_week": "2026-06-19", "one_week_move": 5.9, "four_week_move": -6.6, "twelve_week_move": 6.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.961222, "market_dynamics_buy_signal": false, "relative_strength": -9.078058, "fair_value_gap": 47.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 54.2754, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.9% over one week, -6.6% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "News confirmed by price", "tone": "positive", "classification": "confirmed_positive", "summary": "Constructive news tone is being confirmed by positive weekly price action.", "confidence": 75, "badges": ["Sentiment-trend disagreement", "Positive but stretched"], "opportunities": [], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive.", "Constructive tone is arriving with price materially above fair value."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "Investing.com", "count": 10}, {"label": "Market source", "count": 10}, {"label": "Quiver Quantitative", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Moomoo", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "Stock Traders Daily", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 19}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "65/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "News confirmed by price", "tone": "positive", "text": "Constructive news tone is being confirmed by positive weekly price action."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+5.9% over one week, -6.6% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating"}], "updated_at": "2026-06-22T18:01:39.828144+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}